// Company Overview //
| Stock Name | 滿貫集團控股有限公司 |
| Stock Code | 03390 |
| Company Full Name | 滿貫集團控股有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事銷售及分銷中成藥、保健、皮膚護理、個人護理及及其他健康護理產品。 |
| Listing Date | 2020-04-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港新界沙田坳背灣街38-40號華衛工貿中心8樓14室 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.tycoongroup.com.hk |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Prospectus Date | 2020-03-30 |
| Offer Price | HK$ 1.49 / shares |
| Total Funds Raised | HK$ 28,670,580 |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
// First Day Performance
| First Day Close | Loading... |
| First Day Open | HK$ 1.28 |
| First Day Change | -35.57% |
| First Day Volume | 42646000.0 |
| First Day Turnover | 48608300.0 |
// Price Chart //
// Use of Proceeds
| Use of Proceeds | 1、約30.0%(或67.7百萬港元)預期用于進一步發展我們的供應鏈及零售管理;
2、約15.0%(或33.9百萬港元)預期用于進一步投資于我們的品牌管理,以提高大眾對本集團及產品的認識;
3、約45.0%(或101.6百萬港元)預期用于償還我們部分銀行借款;
4、約10.0%(或22.5百萬港元)預期用作一般營運資金用途。 |
// Underwriting Syndicate //
整体协调人 (2)
申万宏源融资(香港)有限公司
东吴证券国际经纪有限公司
联席账簿管理人 (6)
申万宏源融资(香港)有限公司
东吴证券国际经纪有限公司
中国光大证券(香港)有限公司
浦银国际融资有限公司
越秀证券有限公司
港利资本有限公司
联席牵头经办人 (10)
申万宏源融资(香港)有限公司
东吴证券国际经纪有限公司
中国光大证券(香港)有限公司
浦银国际融资有限公司
越秀证券有限公司
港利资本有限公司
利弗莫尔证券有限公司
华盛资本证券有限公司
淘金者证券(香港)有限公司
亚银至成资本有限公司
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
| 1 |
Jacobson Group Treasury Limited |
79,998,100 HKD |
— |
27.90% |
— |
6 months |
2020-10-15 |
// Directors & Management //
| Chairman | 王嘉俊 |
| Company Secretary | 張玉存 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 王嘉俊(56.01%);華潤醫藥集團有限公司(18.99%);雅各臣科研制藥有限公司(7.07%) |
Disclaimer & Risk Warning
Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.
Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.